Key sodium channel blocker companies, such as SK Biopharmaceuticals, Vertex Pharmaceuticals, Praxis Precision Medicines, Dogwood Therapeutics, Latigo Biotherapeutics, Neurocrine Biosciences ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological ...

Drugs that target sodium channels already exist. Lidocaine, the local anesthetic that is likely familiar to people who have had their mouth numbed for a dental procedure, inhibits sodium channels.

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Because of this similarity, the sodium channel inhibitors developed in the 2000s were often unable to target one subtype without hitting others. “The selectivity was terrible, frankly,” says ...

These studies "demonstrate the potential of the sodium channel inhibitor benzamil as a prototype for an effective, cost-efficient, and targeted therapeutic for skin inflammation," Marinkovich and ...

The decision may also be seen as a vote of confidence for others developing sodium channel inhibitors.

accompanied by increased inflammatory infiltrate within the CNS Until more is known about the effects of sodium channel blocker withdrawal in humans with MS, clinical studies should monitor ...